Here are the most common pitfalls seen in CDMO contracts for first-in-human (FIH) trials, with why they matter and practical mitigations you can apply during negotiation and drafting.
Top pitfalls and how to mitigate them
1) Undefined or blurred scope of work
- Why it matters: Ambiguity leads to scope creep, misaligned timelines, and cost overruns (e.g., what is development vs. GMP manufacturing vs. release testing).
- How to mitigate: Attach a detailed SOW or exhibit listing all deliverables (process development tasks, CTM quantities and formats, fill/finish steps, batch sizes, packaging/labeling, release testing, stability testing, analytical methods, reference standards, documentation deliverables, and acceptance criteria).
2) Weak or missing quality agreement
- Why it matters: Quality responsibilities, CAPA, deviations, OOS handling, and audit rights may be unclear, risking non-compliance.
- How to mitigate: Include a comprehensive quality agreement aligned with ICH Q7/Q8/Q9/Q10, specify QA and QA oversight for batch release, CAPA timeliness, deviation handling, and audit/inspection support.
3) Unclear release criteria and testing plan
- Why it matters: If acceptance criteria, analytical methods, and reference standards are vague, batches may not be reliably released for humans.
- How to mitigate: Define explicit release criteria, reference methods (and method validation status), impurity/aribiquity specs, stability acceptance criteria, and what happens if criteria are not met.
4) Inadequate data integrity and systems controls
- Why it matters: Part 11/ALCOA data integrity issues can derail regulatory submissions and patient safety.
- How to mitigate: Require validated data systems, audit trails, access controls, nightly backups, and a data management plan; specify compliance with applicable data integrity regulations.
5) Unclear regulatory deliverables and support for IND/IMPD
- Why it matters: CDMOs are often relied on for regulatory documentation; gaps can slow or derail submissions.
- How to mitigate: State clearly which documents CDMO will provide (e.g., CMC sections, batch records, stability data, COAs, VMPs), timelines, and the sponsor’s responsibility for final submission assembly. Include a plan for regulatory questions and responses.
6) Change control vulnerability
- Why it matters: Uncontrolled changes to processes, materials, or specs can invalidate data and jeopardize safety.
- How to mitigate: Establish a formal change-control process with written notice, impact assessment (timeline, cost, regulatory), and sponsor approval before implementing changes.
7) Ambiguity around IP and data rights
- Why it matters: Discoveries, improvements, and know-how generated during FIH can have long-term value; unclear rights can hinder future development.
- How to mitigate: Define ownership of background IP, ownership of generated data, licensing terms for sponsor use, field-of-use restrictions, and who can publish or present data.
8) Pricing, changes, and cost management
- Caution: Hidden fees, ambiguous change-order mechanics, and undefined risk-sharing can lead to disputes.
- How to mitigate: Agree on a clear pricing model (fixed price vs. cost-plus with cap), a documented change-order process, milestone-based payments, and explicit handling of backorders, expedited shipping, and storage costs.
9) Capacity, supply security, and single-source risk
- Why it matters: FIH programs require reliable supply of clinical materials; disruptions can halt trials.
- Mitigation: Require capacity commitments, lead times, and contingency plans (backup supplier, dual sourcing for critical materials, incoming/outgoing CTM traceability). Include minimum inventory and safety stock expectations.
10) Raw materials and supplier controls
- Why it matters: Raw material quality, regulatory status, and supplier qualification affect product quality and regulatory readiness.
- Mitigation: Require supplier qualification, approved vendor lists, material specifications, and documented CQAs; demand alternatives if a critical material becomes unavailable.
11) Handling of potent or hazardous materials
- Why it matters: Patient safety and worker safety must be protected; regulatory expectations are high for containment and waste.
- Mitigation: Define containment levels, engineering controls, PPE requirements, decontamination, waste disposal, and spill response procedures; ensure training and certifications are stated.
12) Transition, termination, and post-trial support
- Why it matters: Transitioning CTM and data after stopping can be error-prone and disrupt next steps.
- Mitigation: Include a transition plan, data/model transfer obligations, final material disposition, and defined post-trial support (second sourcing, LOA for ramp-down).
Quick red flags to watch during negotiations
- No or vague quality agreement tying GMP responsibilities to specific personnel or sites.
- Missing IND/IMP regulatory deliverables or no owner for regulatory strategy.
- Unclear acceptance criteria, methods, or reference standards for release.
- Absence of a formal change-control process or unconstrained ability to rework without sponsor input.
- IP/data rights ambiguity or unfavorable transfer of data ownership to the CDMO.
- No backup manufacturing plan or clear exposure to supply disruption.
- Data management systems not aligned with 21 CFR Part 11 or equivalent standards.
- No containment and safety plan for handling potent or hazardous materials.
Practical negotiation tips
- Insist on a integrated appendix with SOW, regulatory deliverables, and quality agreement sections all harmonized.
- Require a risk assessment or FMEA for supply, manufacturing, and data processes.
- Include a defined transition/exit plan and data handover timeline.
- Request milestone-based reviews and stage gates, with explicit go/no-go criteria for progression.
- Ask for a living document approach: contracts updated as development progresses and regulatory expectations evolve.
If you’d like, I can tailor this into:
- A compact red-flag checklist you can run through in vendor calls.
- A more detailed risk register aligned to your specific program (e.g., small molecule vs. biologic, US/EU regulatory scope).
- A draft quality agreement or SOW outline you can adapt for your negotiations.
Would you like me to customize these points to your exact program (type of product, regulatory region, and whether you’re sponsor or CDMO)?